202 completed, 64 recruiting, 46 terminated, 25 unknown. 398 Phase 1, 160 Phase 2.
Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) - Colorectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 64 | 2026-10-20 | 2026-09-28 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months - Advanced Small Intestine Cancer, Appendiceal Cancers | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 22 | 2026-09-18 | 2026-09-25 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-10-26 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| 5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C) - Actinic Keratoses | Phase 1 | Not yet recruiting | Cedars-Sinai Medical Center | 96 | 2026-09-01 | 2026-10-05 |
| A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer HDM2017, Bevacizumab, Oxaliplatin - CRC, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 220 | 2026-08-18 | 2026-09-04 |
| A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer MRG007, 5-Fluorouracil / Leucovorin Calcium, Bevacizumab - Advanced Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Lepu Biopharma Co., Ltd. | 316 | 2026-08-01 | 2026-08-04 |
| Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma Zolbetuximab, Oxaliplatin + 5-Fluorouracil/Leucovorin, CAPOX (oxaliplatin/capecitabine) - GC/GEJC | Phase 1 / Phase 2 | Not yet recruiting | Kaohsiung Medical University Chung-Ho Memorial Hospital | 40 | 2026-06-01 | 2026-07-02 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer BMS-986504, Ipilimumab, Nivolumab - Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-04-07 | 2026-09-16 |
| LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation LPM6690176, Bevacizumab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) - Metastatic Colorectal Cancer (mCRC) | Phase 1 / Phase 2 | Not yet recruiting | Luye Pharma Group Ltd. | 99 | 2026-03-31 | 2026-02-06 |
| Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 35 | 2026-02-16 | 2026-08-19 |
| Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH) - Actinic Keratoses | Phase 1 | Recruiting | West Virginia University | 32 | 2026-02-06 | 2026-04-22 |
| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers Capecitabine, Docetaxel, Fluorouracil - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2025-12-31 | 2025-02-07 | |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-07-22 |
Showing 20 of 398. Sign in to see all of them.
Colorectal Neoplasms (107) · Pancreatic Neoplasms (58) · Rectal Neoplasms (53) · Colonic Neoplasms (44) · Neoplasms (36) · Stomach Neoplasms (33) · Neoplasm Metastasis (31) · Esophageal Neoplasms (29) · Carcinoma, Non-Small-Cell Lung (23) · Squamous Cell Carcinoma of Head and Neck (22) · Head and Neck Neoplasms (18) · Adenocarcinoma (14) · Esophageal Squamous Cell Carcinoma (14) · Adenocarcinoma Of Esophagus (13) · Breast Neoplasms (12)
National Cancer Institute (NCI) (32) · ImmunityBio, Inc. (17) · M.D. Anderson Cancer Center (13) · Memorial Sloan Kettering Cancer Center (11) · Merck Sharp & Dohme LLC (8) · AstraZeneca (7) · City of Hope Medical Center (7) · Mayo Clinic (7) · UNC Lineberger Comprehensive Cancer Center (7) · University of Chicago (7) · Eli Lilly and Company (6) · Massachusetts General Hospital (6) · Astellas Pharma Global Development, Inc. (5) · Dana-Farber Cancer Institute (5) · Pfizer (5)
United States (270) · China (56) · Japan (38) · Spain (31) · France (30) · Australia (24) · Taiwan (24) · South Korea (22) · Canada (20) · Italy (20) · Germany (16) · United Kingdom (16) · Belgium (13) · Switzerland (8) · Israel (7)
Project Leader (4) · Autumn McRee, MD (3) · Howard S. Hochster, MD (3) · Masahiro Asaka, MD, PhD (3) · Apostolia M. Tsimberidou, MD, PhD (2) · Ari Rosenberg, MD (2) · Caio Rocha Lima, MD (2) · Charles S. Fuchs, MD (2)
PMID 32939319, PMID 36940261, PMID 39863139, PMID 12963697, PMID 15863167, PMID 16009951, PMID 17026790, PMID 17084549, PMID 17216531, PMID 17482376, PMID 18299147, PMID 18809314, PMID 19058754, PMID 19212170, PMID 19219674, PMID 19228749, PMID 19233901, PMID 19509178, PMID 19525947, PMID 19738454, PMID 20605352, PMID 22989664, PMID 23083061, PMID 23332384, PMID 23756764, PMID 24356623, PMID 24567516, PMID 24708624, PMID 24819684, PMID 25117066, PMID 25961845, PMID 26135698, PMID 26186556, PMID 26242208, PMID 26287319, PMID 26573078, PMID 26761784, PMID 26808342, PMID 26861740, PMID 26908161, PMID 27055731, PMID 27871319, PMID 28495639, PMID 28498880, PMID 29159476, PMID 29653628, PMID 29691300, PMID 30053670, PMID 30262136, PMID 30302599
2023 (8), 2016 (6), P30CA015083 (5), 2009 (4), 2015 (4), 2017 (4), P30CA033572 (4), 2018 (3), 2019 (2), 2025 (2), P30CA012197 (2), P30CA014599 (2), P30CA016086 (2), P30CA016087 (2), P30CA043703 (2)